Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharma has hit a 1000 prescription milestone for its medicinal hemp products
  • Its products are used to treat severe epilepsy and liver cancer, and are currently being sold in Australia and the U.K.
  • In mid-September, MGC had prescribed its treatments to just 200 patients — making today’s milestone a 400 per cent increase in a month and a half
  • MGC saw a slight bump in its share price over the morning, but shares have since settled to remain flat at 3.4 cents each

Just two weeks after seeing prescriptions tick over the 600 patient line, MGC Pharma has passed the 1000 patient milestone in Australia and the U.K.

In mid-September, the medicinal hemp company had prescribed its cannabinoid medicines to 200 patients — meaning today’s milestone is an increase of roughly 400 per cent in just a month and a half.

The company’s products, CannEpil and MXP100, are prescribed in Australia under the Special Access Scheme and through specialised doctors in the U.K.

CannEpil is a treatment for severe epilepsy that can be taken orally, while MPX100 is used to treat mild neurological disorders, inflammation, and hepatoma (liver cancer).

According to MGC, distribution partner Cannvalate accounts for more than half of all prescriptions to date and is reporting an increasing interest in CannEpil and MPX100.

MGC Co-Founder and Managing Director Roby Zomer said this prescription growth is expected to continue through to the end of the year.

“From a standing start we have now hit 1,000 prescriptions in a short space of time and ahead of schedule, demonstrating a clear demand for MGC Pharma’s products,” Roby commented.

“The established profile of return patients for MGC Pharma products is expected to drive the prescription growth rate through November, December, and beyond,” he said.

The company averaged 25 prescriptions per business day during October, and new purchase orders of more than €300,000 (A$484,000) have been received for all MGC products.

MGC saw a slight bump in its share price over the morning, but shares have since returned to the same price as yesterday’s close. At 1:05 pm AEDT, MGC shares are worth 3.4 cents each in a $46.47 million market cap.

MXC by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.